drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-HER2)
drug_description
Anti-HER2 monoclonal antibody providing ERBB2 blockade and antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody targeting the HER2 (ERBB2) extracellular dimerization domain (domain II); blocks HER2 heterodimerization (e.g., with HER3), inhibiting downstream signaling (PI3K/AKT, MAPK) and inducing tumor cell death, while also mediating Fc-dependent ADCC.
drug_name
Pertuzumab
nct_id_drug_ref
NCT05332561